Pictet Asset Management Holding SA reduced its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 82.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 343,086 shares of the biopharmaceutical company’s stock after selling 1,640,112 shares during the quarter. Pictet Asset Management Holding SA owned about 0.20% of ACADIA Pharmaceuticals worth $6,936,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in ACADIA Pharmaceuticals in the second quarter valued at approximately $569,634,000. Palo Alto Investors LP bought a new stake in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $72,461,629. Bank of America Corp DE bought a new stake in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $32,900,000. First Trust Advisors LP increased its holdings in shares of ACADIA Pharmaceuticals by 47.3% during the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock valued at $74,435,000 after acquiring an additional 1,073,834 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of ACADIA Pharmaceuticals during the second quarter worth approximately $19,244,000. 96.71% of the stock is owned by institutional investors and hedge funds.
ACADIA Pharmaceuticals Stock Performance
Shares of NASDAQ ACAD opened at $18.75 on Monday. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of 8.89 and a beta of 0.87. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $15.85 and a fifty-two week high of $30.96. The firm’s 50-day simple moving average is $21.79 and its 200 day simple moving average is $23.37.
Analyst Upgrades and Downgrades
ACAD has been the topic of a number of research reports. Deutsche Bank lowered their target price on ACADIA Pharmaceuticals from $38.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, September 25th. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, October 19th. UBS Group downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $49.00 to $23.00 in a research report on Tuesday, October 13th. Weiss Ratings restated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, November 10th. Finally, William Blair set a $33.00 price target on shares of ACADIA Pharmaceuticals in a research note on Monday, September 28th. Thirteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $31.34.
Check Out Our Latest Analysis on ACADIA Pharmaceuticals
Insider Transactions at ACADIA Pharmaceuticals
In related news, EVP Mark Schneyer sold 3,321 shares of the company’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $20.88, for a total transaction of $69,342.48. Following the completion of the sale, the executive vice president owned 71,322 shares in the company, valued at approximately $1,489,203.36. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 26.20% of the company’s stock.
ACADIA Pharmaceuticals Profile
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.
Featured Stories
- Five stocks we like better than ACADIA Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
